21:59 , May 22, 2018 |  BC Extra  |  Company News

Management tracks: Trevena, Galecto

Neurology company Trevena Inc. (NASDAQ:TRVN) hired Mark Demitrack as SVP and CMO. He was VP of clinical strategy at Roivant Sciences GmbH (Basel, Switzerland). Galectin modulator company Galecto Biotech AB (Copenhagen, Denmark) hired Richard Marshall...
20:25 , Dec 9, 2016 |  BC Week In Review  |  Company News

Purdue, AnaBios deal

The companies partnered to develop non-opioid, non- NSAID treatments for chronic pain. Purdue granted AnaBios rights to a suite of patents for Nav1.7 (SCN9A) sodium ion channel blockers. AnaBios will use its Phase-X discovery platform...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Epirus, AnaBios deal

Epirus (formerly Zalicus Inc. ) granted CRO AnaBios exclusive, worldwide rights to develop and commercialize the biotech’s preclinical-stage sodium channel modulator portfolio, including IP and related pipeline assets. The products include compounds that block the...
07:00 , Jun 23, 2014 |  BioCentury  |  Product Development

Nav(1.7)igating pain

Data reported by Convergence Pharmaceuticals Ltd. last week for CNV1014802 to treat trigeminal neuralgia gave the first Phase II evidence that systemic Nav1.7 blockers can treat pain safely and effectively. The data also lend further...